InvestorsHub Logo
Followers 19
Posts 1027
Boards Moderated 0
Alias Born 06/28/2013

Re: erostratus post# 6372

Saturday, 12/21/2013 6:16:02 PM

Saturday, December 21, 2013 6:16:02 PM

Post# of 48316
Also, another reason why ICT-107 failed, scratch that, why ALL cancer vaccines fail is the antigen targeting system.
I've been in a debate with NWBO longs over this very issue as they think the fuller antigen profile of D-Vax will make up for the horror seen in IMUC.
I think that's a rather shaky bet.
The moment you introduce such secondary mechanisms such as antigen systems, you're opening up the room for error. Tumors constantly adapt as there are thousands upon thousands of subtypes and the antigen profile recognized for one will not be recognized for the other (within the same person even). Or even if they are the correct antigens there is never a guarantee that the loading into the dendritic cells will lead to a proper structuring within the Tcells. Plainly put: you never know if the drug is even reaching the tumor. The moment you introduce antigen systems, you're opening up one other venue for error. ICT-107's synthetic antigen profile might have not been recognized by the tumors at all, as those antigens were probably never expressed within that specific tumor. ICT-107 probably never reached its target for most people..hence the disaster. people are saying that NWBO has a fuller antigen profile which will make up for this. This might be true. I'm just very skeptical and steering the f away from it.

Why muddle up things with antigen systems.

Here comes in the beauty of $ONCS IMMUNOPULSE. The IL-12 plasmid is being directly applied into the tumor's cells through electroporation. No need for anigen systems. No room for error. We know the drug is reaching its target because we are LITERALLY applying the DNA plasmid directly into the tumor's cells themselves.
Simpler. Better. Stronger